Thymidylate Synthase Protein Expression in Primary Colorectal Cancer: Lack of Correlation With Outcome and Response to Fluorouracil in Metastatic Disease Sites
- 1 March 2003
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (5) , 815-819
- https://doi.org/10.1200/jco.2003.07.039
Abstract
Purpose: The aim of this study was to investigate the utility of quantitating thymidylate synthase (TS) in the primary tumor as a surrogate for metastatic disease sites to predict the likelihood of response and outcome to fluorouracil (FU) treatment in patients with metastatic colorectal cancer. Methods: TS protein expression was evaluated using the TS 106 antibody and the avidin biotin labeling immunohistochemical technique in primary tumor samples from 219 patients with metastatic colorectal cancer. The patients were a representative sample of those patients enrolled into the Eastern Cooperative Oncology Group E2290 protocol that evaluated five separate FU-containing regimens in patients with metastatic residual or recurrent colorectal carcinoma. Results: Our retrospective analysis found that the level and extent of TS protein expression in the primary tumor did not correlate with overall survival in patients with metastatic or recurrent colorectal cancer. A trend toward a direct correlation between the level of TS protein expression and response was noted in tumors that expressed high TS levels. This response advantage for patients expressing high TS levels in the primary tumor was apparent regardless of what FU-based treatment the patient received but was most apparent in the subgroup treated with leucovorin, in which the level of TS expression and response to FU and leucovorin reached statistical significance (P = .034). No significant interaction could be detected between the addition of leucovorin to FU and the level of TS expression in the primary tumor. Conclusion: This study demonstrated that measurement of TS protein levels in the primary tumor tissue does not aid in predicting outcome or response to FU in a metastatic disease site. These assays must be performed on biopsy tissue from the metastatic disease site that is used to radiologically assess response and outcome to treatment.Keywords
This publication has 12 references indexed in Scilit:
- Investigation of the Prognostic and Predictive Value of Thymidylate Synthase, p53, and Ki-67 in Patients With Locally Advanced Colon CancerJournal of Clinical Oncology, 2002
- Bax Expression Decreases Significantly From Primary Tumor to Metastasis in Colorectal CancerJournal of Clinical Oncology, 2002
- Thymidylate Synthase Pharmacogenetics in Colorectal CancerClinical Colorectal Cancer, 2001
- Fluorouracil Modulation in Colorectal Cancer: Lack of Improvement With N -Phosphonoacetyl- l -Aspartic Acid or Oral Leucovorin or Interferon, But Enhanced Therapeutic Index With Weekly 24-Hour Infusion Schedule—An Eastern Cooperative Oncology Group/Cancer and Leukemia Group B StudyJournal of Clinical Oncology, 2001
- Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patientsBritish Journal of Cancer, 2000
- Thymidylate synthase (TS) protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil (5FU)European Journal Of Cancer, 1999
- Resistance to Tomudex (ZD1694): Multifactorial in human breast and colon carcinoma cell linesBiochemical Pharmacology, 1996
- New Concepts for the Development and Use of AntifolatesThe International Journal of Cell Cloning, 1996
- Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell linesBritish Journal of Cancer, 1995
- Thymidylate synthetase - a target enzyme in cancer chemotherapyBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1977